Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on therapies for rare cardiopulmonary disease, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). News about Liquidia often centers on its treprostinil‑based portfolio, including YUTREPIA™ (treprostinil) inhalation powder, the investigational L606 treprostinil liposome inhalation suspension, and its role in promoting generic Treprostinil Injection in the United States.
On this page, readers can follow company announcements related to YUTREPIA’s commercial launch, prescription trends and patient starts, as well as updates from ongoing clinical programs such as the ASCENT study in PH‑ILD. Liquidia regularly reports interim clinical data, including safety and exploratory efficacy findings, and provides context on how these results may inform treatment of PAH and PH‑ILD.
Investors and observers will also find coverage of quarterly financial results, revenue contributions from YUTREPIA and Treprostinil Injection, and details of corporate developments disclosed in press releases and SEC filings. These include financing arrangements, manufacturing expansion in Morrisville, North Carolina, and licensing agreements such as the exclusive U.S. license with Vectura for a nebulizer device used with L606.
In addition, Liquidia frequently participates in medical and investor conferences, R&D days and scientific meetings, where it presents new data on YUTREPIA and L606 and discusses its strategy in pulmonary hypertension. This news feed helps track how Liquidia advances its PRINT®‑enabled inhaled therapies, navigates litigation and regulatory milestones, and communicates with the medical and investment communities over time.
Liquidia Technologies (NASDAQ: LQDA) has appointed Steven Bariahtaris as interim Chief Financial Officer following the resignation of Richard Katz. Bariahtaris brings nearly 24 years of experience from Johnson & Johnson, where he held several executive roles. His appointment comes as Liquidia prepares for the acquisition of RareGen and the potential launch of LIQ861, aimed at treating pulmonary arterial hypertension. CEO Neal Fowler emphasized Bariahtaris's strategic insights and financial expertise as crucial for the company's growth during this transformative period.
Liquidia Technologies (LQDA) has received FDA acceptance for its New Drug Application (NDA) for LIQ861, targeting pulmonary arterial hypertension (PAH), with a Prescription Drug User Fee Act (PDUFA) goal date set for November 24, 2020. The company reported no revenues for Q2 2020, a decrease from $8.1 million in Q2 2019, resulting in a net loss of $13.9 million. R&D expenses decreased while G&A expenses rose significantly due to legal costs associated with the RareGen acquisition. Liquidia raised $75 million from a public offering and appointed Tushar Shah, M.D. as Chief Medical Officer.
Liquidia Technologies (Nasdaq: LQDA) will have its CEO, Neal Fowler, present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 10:20 AM ET. The event will highlight Liquidia's focus on developing novel biopharmaceutical products using its proprietary PRINT® technology, aimed at enhancing patient outcomes. Liquidia is currently developing two primary candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for postoperative pain. A live audio webcast will be available for attendees.
Liquidia Technologies (LQDA) reported exploratory endpoint data from the INSPIRE study of LIQ861 for pulmonary arterial hypertension (PAH) during the ATS Annual Meeting. LIQ861, an inhaled dry powder formulation, showed improvements after two months, including increased six-minute walk distance and reduced Minnesota LIVING WITH HEART FAILURE Questionnaire scores. Over 70% of subjects titrated to higher doses, with 93% tolerating the treatment well. Liquidia has submitted a New Drug Application for LIQ861, awaiting FDA review by November 24, 2020.
Liquidia Technologies (Nasdaq: LQDA) announced plans to release its second quarter 2020 financial results on August 10, 2020. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide corporate updates. The company focuses on developing novel therapeutics using its proprietary PRINT® technology, primarily targeting pulmonary arterial hypertension (PAH) with its product candidate LIQ861 and local post-operative pain with LIQ865. Liquidia aims to improve patient outcomes through precise drug particle production.
Liquidia Technologies (LQDA) announced an amended complaint from United Therapeutics Corporation regarding alleged patent infringement related to its pulmonary arterial hypertension treatment, LIQ861. The original complaint, filed in June 2020, triggered a 30-month regulatory stay on LIQ861's FDA approval. However, the new patent allegations do not affect the review timeline. Liquidia asserts that LIQ861 offers a beneficial treatment option for patients, and the company is committed to defending its position vigorously.
Liquidia Technologies (NASDAQ: LQDA) has successfully closed a public offering of 9,375,000 shares at $8.00 each, generating total gross proceeds of $75 million. This offering follows a previously filed registration statement with the SEC. The underwriters have a 30-day option to purchase an additional 1,406,250 shares. Jefferies acted as the sole book-running manager with Needham & Company and Wedbush PacGrow as co-managers. The securities will not be offered where prohibited by state laws.
Liquidia Technologies (NASDAQ: LQDA) will host a webcast and conference call on June 30, 2020, at 8:00 a.m. ET to discuss updates regarding the proposed acquisition of RareGen and an ongoing common stock offering. Investors can join via domestic dial-in (1-877-707-8711) or international dial-in (1-857-270-6219) using passcode 4836889. Liquidia focuses on innovative drug delivery via PRINT® technology, targeting conditions like pulmonary arterial hypertension (LIQ861) and post-operative pain (LIQ865). For more details, visit Liquidia's website.
Liquidia Technologies, Inc. (NASDAQ: LQDA) announced a public offering of 9,375,000 shares of common stock at $8.00 each, yielding gross proceeds of $75 million. This offering is solely by Liquidia, with a 30-day option for underwriters to purchase an additional 1,406,250 shares. The transaction is expected to close on July 2, 2020. Jefferies serves as the sole book-running manager. The offering is conducted under a shelf registration statement declared effective by the SEC in September 2019, and related documents can be accessed via the SEC website.
Liquidia Technologies (NASDAQ: LQDA) has announced its acquisition of RareGen, LLC, enhancing its capabilities in pulmonary arterial hypertension (PAH) treatment. The all-stock merger, expected to close in Q4 2020, will create Liquidia Corporation and allow it to promote RareGen's generic treprostinil. This strategic move is aimed at improving the company's commercial readiness for LIQ861, an inhaled treatment for PAH. The merger is set to bolster Liquidia's market presence, integrating RareGen's sales force and expertise in rare diseases.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
